Alectinib · Alecensa

What is Alectinib?

Alectinib is an oral tyrosine kinase inhibitor that targets ALK and RET. It inhibits ALK phosphorylation and ALK-mediated signaling through STAT3 and AKT, reducing tumor cell viability in ALK-driven cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Alecensa

Drug type

Small molecule

Targets

ALK, RET (secondary target)

Mechanism

Inhibitor of ALK

Pathways

STAT3 signaling, PI3K/Akt signaling

Therapy area

Oncology

Developer

Hoffmann-La Roche

In trials of

NUVL

FDA status

Approved as Alecensa (December 11, 2015), NDA208434 · FDA label

✅ FDA-approved uses

• Adjuvant treatment of ALK-positive non-small cell lung cancer following tumor resection
• Treatment of ALK-positive metastatic non-small cell lung cancer

From the indications section of the FDA label (version of Aug 21, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Anaplastic Lymphoma Kinase-positiveNon-small Cell Lung Cancer

Other drugs acting on ALK

Sources

• FDA label (DailyMed)
• FDA label Alecensa (2026-08-21), indications
• NCI Thesaurus

Updated Oct 3, 2026.